Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Prasanna Kumar Nidamarthy"'
Autor:
Edwin Wong, Carla Nester, Teresa Cavero, Alexandre Karras, Moglie Le Quintrec, Liz Lightstone, Ute Eisenberger, Maria Jose Soler, David Kavanagh, Erica Daina, Manuel Praga, Nicholas R. Medjeral-Thomas, Anja Gäckler, Clara Garcia-Carro, Andrea Biondani, Frederique Chaperon, Kenneth Kulmatycki, Julie Milojevic, Nicholas J.A. Webb, Prasanna Kumar Nidamarthy, Guido Junge, Giuseppe Remuzzi
Publikováno v:
Kidney International Reports, Vol 8, Iss 12, Pp 2754-2764 (2023)
Introduction: Complement 3 glomerulopathy (C3G) is a rare inflammatory kidney disease mediated by dysregulation of the alternative complement pathway. No targeted therapy exists for this aggressive glomerulonephritis. Efficacy, safety, tolerability,
Externí odkaz:
https://doaj.org/article/4142dfa19bbe4b318478e3240af7c53c
Autor:
Jun Ho Jang, Lily Wong, Bor-Sheng Ko, Sung-Soo Yoon, Katie Li, Irina Baltcheva, Prasanna Kumar Nidamarthy, Raghav Chawla, Guido Junge, Eng Soo Yap
Publikováno v:
Blood Advances. 6:4450-4460
Iptacopan (LNP023) is a novel, oral selective inhibitor of complement factor B under clinical development for paroxysmal nocturnal hemoglobinuria (PNH). In this ongoing open-label phase 2 study, PNH patients with active hemolysis were randomized to r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::403d8dcad4fce9290331cf5e3c284469
https://doi.org/10.1182/bloodadvances.2022006960
https://doi.org/10.1182/bloodadvances.2022006960
Autor:
Bharti Shah, Jin Chen, Rowan Stringer, William T Prince, Melissa Hackling, Leonel Reis da Silva Torrao, Prasanna Kumar Nidamarthy, Ralph Woessner, Jessie Gu
Publikováno v:
Journal of clinical pharmacologyReferences. 62(4)
Tropifexor, a non-bile acid farnesoid X receptor (FXR) agonist, has dose-proportional pharmacokinetics (PK) and no obvious major enterohepatic circulation. This open-label study investigated the effect of hepatic impairment (HI), as determined by Chi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::348341271586fe04a63e8b02c245e341
https://pubmed.ncbi.nlm.nih.gov/34738233
https://pubmed.ncbi.nlm.nih.gov/34738233
Autor:
Xiaoming Cui, Martin Wermke, Monica Giovannini, Hendrik-Tobias Arkenau, Richard Greil, Prasanna Kumar Nidamarthy, Jeffrey Yachnin, Margarita Majem, Jean-Rene Basque, Victor Moreno, Shruti Kapoor
Publikováno v:
CLINICAL THERAPEUTICS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Altres ajuts: Novartis Pharmaceuticals Corporation. Purpose: In the Phase II GEOMETRY mono-1 study, the potent and selective mesenchymal-epithelial transition (MET) inhibitor capmatinib exhibited considerable efficacy in MET exon 14 skipping (METex14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8515b49d706dde9f2c7d19fccea6840
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4660
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4660
Autor:
Régis Peffault de Latour, Alexander Röth, Prasanna Kumar Nidamarthy, Camilla Frieri, Izabela Rozenberg, Antonio M. Risitano, Peter End, Juliette Soret, Serena Marotta, Flore Sicre de Fontbrune, Ferras Alashkar, Lina Benajiba, Guido Junge, Luana Marano, Julie Milojevic
The haematological benefit of standard-of-care anti-C5 treatment for haemolytic paroxysmal nocturnal haemoglobinuria is limited by residual intravascular haemolysis or emerging C3-mediated extravascular haemolysis. Therefore, the aim of this phase 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::669b69dedf0847b0e54cfa115d20af1e
https://www.ncbi.nlm.nih.gov/pubmed/33765419
https://www.ncbi.nlm.nih.gov/pubmed/33765419
Autor:
Izabela Rozenberg, Lily Ll Wong, Jun-Ho Jang, Eng Soo Yap, Prasanna Kumar Nidamarthy, Katie Li, Guido Junge, Sung-Soo Yoon, Raghav Chawla, Bor-Sheng Ko
Publikováno v:
Blood. 138:2173-2173
Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematological disorder caused by somatic mutations in the phosphatidylinositol glycan A (PIGA) gene in hematopoietic stem cells, resulting in complement alternative pathway (AP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eec18e3e85d3326a7ba5000df2153bab
https://doi.org/10.1182/blood-2021-152518
https://doi.org/10.1182/blood-2021-152518
Autor:
Timothy P. Hughes, Jeffrey H. Lipton, Anna G. Turkina, Ong Tee Chuan, Kudrat Abdulkadyrov, Jonathan Hwang, Hang Quach, Lee-Yung Shih, Vernon J. Louw, Eduardo Ciliao Munhoz, Alaa Elhaddad, Jake Shortt, Luis Meillon, Prasanna Kumar Nidamarthy, Carolina Pavlovsky, Darshan Dalal
Publikováno v:
Blood. 124:4542-4542
Background: In pts with newly diagnosed CML-CP, NIL 300 mg twice daily (BID) is generally well tolerated and results in high rates of molecular response and low rates of disease progression. The kinetics of molecular response achieved with NIL, as as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84f2414adee4796443eba7b82131d1f6
https://doi.org/10.1182/blood.v124.21.4542.4542
https://doi.org/10.1182/blood.v124.21.4542.4542
Autor:
K Govind Babu, Xiao-Jun Huang, Sandip Shah, Jorge E. Cortes, Tomasz Sacha, Carmen Piccolo, Zhizhou Liang, Tomasz Szczudlo, Tina Owugah, Philipp le Coutre, Prasanna Kumar Nidamarthy, José Luis López, Israel Bendit, Carmino Antonio De Souza, Eduardo Bullorsky, Manuel Ayala
Publikováno v:
Blood. 122:95-95
Introduction The phase 3 LASOR trial is the only randomized trial that compares the effects of imatinib dose escalation with those of switching to nilotinib in pts with Philadelphia chromosome–positive (Ph+) CML-CP who experience suboptimal respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e621e3109ba45258a6dcd294b4a6f42
https://doi.org/10.1182/blood.v122.21.95.95
https://doi.org/10.1182/blood.v122.21.95.95